Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BG-C477

Antibody-drug conjugate · Cytotoxic, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer
1 Registered trials

What is BG-C477?

BG-C477 is an antibody-drug conjugate in which a monoclonal antibody binds CEACAM5, a cell adhesion protein overexpressed on many cancer cells, and delivers an undisclosed cytotoxic agent after internalization. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Mechanism
Cytotoxic, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06596473 Phase 1 Advanced Solid Tumors Recruiting ONC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on CEACAM5

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BG-C477

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.